Not logged in.png)
Share.png)
SaveShare Save Share Save EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE, NON-DIABETIC, ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS
Eriksson, Robert; Broberg, Brian V.; Ishoy, Pelle Lau; Bak, Nikolaj; Andersen, Ulrik B.; Jorgensen, Niklas R.; Knop, Filip K.; Ebdrup, Bjorn Share Save Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral DensityEriksson, Robert; Broberg, Brian, V; Ishoy, Pelle L.; Bak, Nikolaj; Andersen, Ulrik B.; Jorgensen, Niklas R.; Knop, Filip K.; Ebdrup, Bjorn H. Share Save Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysisSiskind, Dan; Hahn, Margaret; Correll, Christoph U.; Fink-Jensen, Anders; Russell, Anthony W.; Bak, Nikolaj; Broberg, Brian V.; Larsen, Julie; Ishoy, Pelle L.; Vilsboll, Tina; Knop, Filip K.; Kisely, Steve; Ebdrup, Bjorn H. Share Save Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trialEbdrup, Bjorn H.; Broberg, Brian V.; Ishoy, Pelle L.; Bak, Nikolaj; Andersen, Ulrik B.; Jorgensen, Niklas R.; Holst, Jens J.; Knop, Filip K.; Glenthoj, Birte Y. Share Save Share Save Share Save Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trialIshoy, Pelle L.; Knop, Filip K.; Broberg, Brian V.; Bak, Nikolaj; Andersen, Ulrik B.; Jorgensen, Niklas R.; Holst, Jens J.; Glenthoj, Birte Y.; Ebdrup, Bjorn H. Share Save Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
